| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC7154 | BMS-833923 (XL-139) Featured | BMS 833923 is an orally bioavailable inhibitor of Smo. It blocks binding of BODIPY cyclopamine (IC50 = 21 nM) and inhibits Gli activation in cell lines that express wild-type Smo or activated mutant forms of Smo (IC50s = 6-35 nM). BMS 833923 robustly inhi |
|
| DC7090 | BMS-863233 (XL-413) Featured | BMS-863233, also known as XL-413, is an orally bioavailable cell division cycle 7 homolog (CDC7) kinase inhibitor with potential antineoplastic activity. |
|
| DC23891 | BMS-869780 | BMS-869780 is a potent γ-secretase modulator (GSM) that decreases Aβ1-42 (IC50=5.1 nM) and Aβ1-40 (IC50=25.1 nM) and increases Aβ1-37 and Aβ1-38 without inhibiting overall levels of Aβ peptides or other APP processing intermediates. |
|
| DC20817 | BMS-871 | BMS-871 is a potent, orally active pan-Notch inhibitor with IC50 of 4/1/4/3 nM for Notch1/2/3/4, respectively. |
|
| DC20818 | BMS-884775 | BMS-884775 is a potent, selective P2Y1 antagonist with IC50 of 0.12 nM. |
|
| DC11990 | BMS-901715 | BMS-901715 is a potent, selective adapter protein-2 associated kinase 1 (AAK1) inhibitor.. |
|
| DC11862 | BMS-906024 | BMS-906024 is a highly potent, selective inhibitor of γ-secretase mediated signaling of Notch1/2/3/4 receptors with IC50 of 1.6/0.7/3.4/2.9 nM, respectively. |
|
| DC4175 | BMS-911543 Featured | BMS-911543 is a potent and selective inhibitor of JAK2 with IC50 of 1.1 nM, approximately 350-, 75- and 65-fold selective to JAK1, JAK3 and TYK2, respectively. |
|
| DC20819 | BMS-919373 | BMS-919373 is a potent I(Kur)/Kv1.5 channel blocker with IC50 of 50 nM, with selectivity versus hERG, Na, Ca channels and reduced the level of brain penetration. |
|
| DC23872 | BMS-932481(BMS932481;BMS 932481) Featured | BMS-932481 (BMS932481) is a potent, selective, orraly active γ-secretase modulator (GSM), shows selectivity for Aβ40 and Aβ42 reduction (IC50=6.6 nM) while sparing total Aβ levels both in vitro and in vivo. |
|
| DC22445 | BMS-933043 | BMS-933043 is a novel highly selective, potent α7 nAChR partial agonist with binding Ki of 3.3 and 8.1 nM for rat and human α7, respectively. |
|
| DC23411 | BMS-952048(BMS952048;BMS 952048) | BMS-952048 is a positive allosteric modulator of mGluR5 with EC50 of 10 nM.. |
|
| DC21092 | BMS-955176 Featured | BMS-955176 (GSK-3532795) is a second-generation HIV-1 maturation inhibitor that exhibits potent activity (EC50=3.9±3.4 nM) against a library (n=87) of gag/pr recombinant viruses. |
|
| DC20820 | BMS-961955 | BMS-961955 is an potent, allosteric inhibitor of HCV NS5B polymerase with EC50 of 7.9/4.3 nM for GT 1b/1a replicon respectively. |
|
| DC20821 | BMS-962212 Featured | BMS-962212 is a potent, highly selective and reversible small molecule coagulation Factor XIa (FXIa) inhibitor with Ki of 0.7 nM. |
|
| DC23143 | BMS-983970 | BMS-983970 (BMS983970) is a potent, orally active, pan-Notch inhibitor, demonstrates robust anti-tumor activity at tolerated doses in multiple tumor xenograft models.. |
|
| DC22035 | BMS-984923 | BMS-984923 (BMS-984923) is a potent silent allosteric modulator (SAM) of mGluR5 with competitive antagonism of MPEPy binding with Ki of 0.6 nM, but has no detectable agonist and antagonist activity at mGluR5 signaling. |
|
| DC10459 | BMS-986020 Featured | BMS-986020 is an LPA1 antagonist. |
|
| DC23873 | BMS-986115 | BMS-986115 is an orally bioavailable, γ-secretase and pan-Notch inhibitor with potential antineoplastic activity. |
|
| DC23459 | BMS-986118 | BMS-986118 is a potent and selective GPR40 agonist with EC50 of 70 and 63 nM for hGPR40 and mGPR40, shows no PPARγ activity (EC50>47 uM). |
|
| DC11923 | BMS-986120 Featured | BMS-986120 (BMS986120) is a potent, selective, orally bioavailable, and reversible PAR4 antagonist with Kd of 0.098 nM for human PAR4. |
|
| DC26073 | BMS-986122 Featured | BMS-986122 is a potent positive allosteric modulator of μ-opioid receptor, significantly increases the inhibition of forskolin-stimulated adenylyl cyclase activity produced by an EC10 (30 pM) concentration of endomorphin-I in CHO-μ cells.. |
|
| DC11819 | BMS-986142 Featured | BMS-986142 is a potent, selective, and reversible BTK (Bruton’s tyrosine kinase) inhibitor (BTK IC₅₀ = 0.5nM; human WB IC₅₀ = 90 nM). |
|
| DC10609 | BMS-986158 Featured | BMS-986158 is an inhibitor of the bromodomain and extra-terminal (BET) proteins. |
|
| DC23609 | BMS-986163 | BMS-986163 is a water-soluble phosphate prodrug of BMS-986169, which is a novel GluN2B negative allosteric modulator (Ki=4.0 nM).. |
|
| DC12174 | Deucravacitinib(BMS986165) Featured | BMS-986165 is a selective, potent, allosteric inhibitor of tyrosine kinase 2 (Tyk2). |
|
| DC23532 | BMS-986166 Featured | BMS-986166 (BMS986166) is a potent, selective S1P receptor modulator for the treatment of ulcerative colitis.. |
|
| DC23639 | BMS-986169 | BMS-986169 is a novel GluN2B negative allosteric modulator, demonstrates high binding affinity for the GluN2B allosteric site (Ki=4.0 nM) and selective inhibition of GluN2B receptor function (IC50=24 nM) in cells. |
|
| DC23460 | BMS986187 Featured | BMS-986187 is a novel potent, positive allosteric modulator of δ-opioid receptor with EC50 of 30 nM, 100-fold selectivity over μ-opioid receptor.. |
|
| DC12030 | BMS-986195 Featured | BMS-986195 is a potent, covalent, irreversible inhibitor of Bruton’s tyrosine kinase (BTK). |
|
